title: Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.
abstract: Hodgkin lymphoma (HL) is characterized by a minority of neoplastic Hodgkin-Reed Sternberg (HRS) cells surrounded by a non-neoplastic reactive infiltrate. As immunological mechanisms appear to be crucial in classical HL pathogenesis, altered serum chemokine levels might be related to disease activity. Serum levels of nine chemokines were examined in 163 untreated HL patients and 334 controls. We investigated single nucleotide polymorphisms (SNPs) for association with serum CCL17 (thymus and activation-regulated chemokine, TARC) levels and HL susceptibility. Serum CCL17 and CCL22 (macrophage-derived chemokine, MDC) levels were significantly increased in 82% and 57% of the HL patients. Nodular sclerosis cases showed increased serum CCL17 and CCL22 levels (P < 0.001) and serum levels were correlated with Ann Arbor stage. Of nine patients with pre- and post-treatment serum samples, the majority showed decreased CCL17 and CCL22 levels after treatment. HRS cells expressed CCL17 and CCL22 in 77% and 75% of 74 cases. Three SNPs showed a trend of increased serum CCL17 levels with minor alleles in controls, but were not associated with HL susceptibility. CCL17 and CCL22 were the only chemokines with increased serum levels in the vast majority of HL patients, which provides further insight into the molecular mechanism(s) leading to infiltrations of reactive lymphocytes in HL.
authors.affiliation: Department of Medical Genetics, Unviersity Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: Marijke
authors.initials: M
authors.lastname: Niens
authors.forename: Lydia
authors.initials: L
authors.lastname: Visser
authors.forename: Ilja M
authors.initials: IM
authors.lastname: Nolte
authors.forename: Gerrit
authors.initials: G
authors.lastname: van der Steege
authors.forename: Arjan
authors.initials: A
authors.lastname: Diepstra
authors.forename: Pablo
authors.initials: P
authors.lastname: Cordano
authors.forename: Ruth F
authors.initials: RF
authors.lastname: Jarrett
authors.forename: Gerard J
authors.initials: GJ
authors.lastname: Te Meerman
authors.forename: Sibrand
authors.initials: S
authors.lastname: Poppema
authors.forename: Anke
authors.initials: A
authors.lastname: van den Berg
mesh_terms: D054414:Chemokine CCL17 / Q000097:blood*; D054422:Chemokine CCL22 / Q000097:blood*; D018925:Chemokines / Q000097:blood; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006689:Hodgkin Disease / Q000097:blood* / Q000235:genetics / Q000473:pathology; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood*; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide
chemical_list: C106230:CCL17 protein, human; C515482:CCL22 protein, human; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D018925:Chemokines; D009363:Neoplasm Proteins